The role of PET / CT in peripheral T‐cell lymphoma: Results from the PET / CT substudy of the UK NCRI phase 2 CHEMO ‐T trial
British Journal of Haematology · 2025-08 · 207 (2) · 407-416
DOI: 10.1111/bjh.20160 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift British Journal of Haematology, online erschienen am 26.05.2025. Verfasst von M Gleeson und 18 weiteren Autor:innen. Beteiligte Einrichtung: Guy's and St Thomas' NHS Foundation Trust, London, UK. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Lymphoma, T-Cell, Peripheral, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Bloodwise, The UK National Health Service provided funding to the UK National Institute for Health Research (NIHR) Biomedical Research Centres at The Royal Marsden Hospit…, The Blood Theme of the Oxford National Institute for Health Research Biomedical Research Centre (Oxford, UK).
Abstract (Originalsprache)
The UK National Cancer Research Institute (NCRI) phase 2 randomised CHOP versus GEM‐P in previously untreated patients with peripheral T‐cell lymphoma (CHEMO‐T) trial compared the regimens of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) and gemcitabine, cisplatin and methylprednisolone (GEM‐P) in treatment‐naïve patients with peripheral T‐cell lymphoma (PTCL). Evaluation of the role of positron emission tomography/computed tomography (PET/CT) was a key secondary end‐point. All patients required PET/CT, contrast‐enhanced CT (CECT) and bone marrow biopsy (BMB) at enrolment and end of treatment (EOT). Baseline (BL) data for PET/CT ( BL PET/CT), CECT and BMB were compared. Response by CECT and PET/CT was correlated with outcomes. BL PET/CT data were available for 82/84; 98% (80/82) had FDG‐avid disease. BL PET/CT altered disease stage in 43% and identified additional extranodal sites (most frequently bone marrow/bone n = 7) in 25% versus CECT. Concordance of BL PET/CT with BMB for marrow involvement was 72.6%, with discordant results for n = 20. Ten patients with biopsy‐proven marrow infiltration had a PET/CT‐negative marrow. However, BL PET/CT detected marrow involvement in patients with a negative BMB ( n = 10), predominantly cases with focal uptake (7/10). At EOT, a negative PET/CT (vs. positive) was associated with superior 2‐year progression‐free survival (PFS) of 55% (95% CI: 38%–70%) versus 29% (95% CI: 12%–48%) [HR 0.45 (95% CI: 0.23–0.88), p = 0.021], respectively, which remained independently prognostic. Our findings indicate that PET/CT should be incorporated as a standard of care in the management of PTCL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guy's and St Thomas' NHS Foundation Trust, London, UK.
- The Royal Marsden NHS Foundation Trust, London and Surrey, UK.
- Cancer Research UK Centre, University of Southampton, Southampton, UK.
- Olivia Newton John Cancer Research Centre, Austin Health, Melbourne, Australia.
- Monash University, Melbourne, Australia.
- Blackpool Victoria Hospital, Blackpool, UK.
ORCID-Profile: M Gleeson, D Cunningham, E A Hawkes, K Cwynarski
Förderung
- Bloodwise
- The UK National Health Service provided funding to the UK National Institute for Health Research (NIHR) Biomedical Research Centres at The Royal Marsden Hospit…
- The Blood Theme of the Oxford National Institute for Health Research Biomedical Research Centre (Oxford, UK)
- National Institute for Health and Care Research
Zitieren
APA
Gleeson, M., Gonzalez Arias, C., Cunningham, D., Peckitt, C., Thomas, K., Du, Y., Hujairi, N., To, Y. M., Chen, H. C., Patel, S., Chau, I., Johnson, P., Wotherspoon, A., Attygalle, A. D., Hawkes, E. A., Macheta, M. P., Collins, G. P., Cwynarski, K., & Chua, S. (2025). The role of PET / CT in peripheral T‐cell lymphoma: Results from the PET / CT substudy of the UK NCRI phase 2 CHEMO ‐T trial. British Journal of Haematology, 207(2), 407-416. https://doi.org/10.1111/bjh.20160
Vancouver
Gleeson M, Gonzalez Arias C, Cunningham D, Peckitt C, Thomas K, Du Y, et al. The role of PET / CT in peripheral T‐cell lymphoma: Results from the PET / CT substudy of the UK NCRI phase 2 CHEMO ‐T trial. British Journal of Haematology. 2025;207(2):407-416. doi:10.1111/bjh.20160
BibTeX
@article{Gleeson2025,
author = {Gleeson, M and Gonzalez Arias, C and Cunningham, D and Peckitt, C and Thomas, K and Du, Y and Hujairi, N and To, Y M and Chen, H C and Patel, S and Chau, I and Johnson, P and Wotherspoon, A and Attygalle, A D and Hawkes, E A and Macheta, M P and Collins, G P and Cwynarski, K and Chua, S},
title = {The role of PET / CT in peripheral T‐cell lymphoma: Results from the PET / CT substudy of the UK NCRI phase 2 CHEMO ‐T trial},
journal = {British Journal of Haematology},
year = {2025},
volume = {207},
number = {2},
pages = {407--416},
doi = {10.1111/bjh.20160}
}
EUVIMED